Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Comparative therapeutic potential of ALX-0171 and palivizumab against RSV clinical isolate infection of well-differentiated primary pediatric bronchial epithelial cell cultures

Lindsay Broadbent, Hong Guo Parke, Lyndsey J. Ferguson, Andrena Miller, Michael D. Shields, Laurent Detalle, Ultan F. Power
doi: https://doi.org/10.1101/800326
Lindsay Broadbent
aWellcome-Wolfson Institute for Experimental Medicine, Queens University Belfast, Belfast, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hong Guo Parke
aWellcome-Wolfson Institute for Experimental Medicine, Queens University Belfast, Belfast, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lyndsey J. Ferguson
aWellcome-Wolfson Institute for Experimental Medicine, Queens University Belfast, Belfast, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrena Miller
aWellcome-Wolfson Institute for Experimental Medicine, Queens University Belfast, Belfast, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael D. Shields
aWellcome-Wolfson Institute for Experimental Medicine, Queens University Belfast, Belfast, United Kingdom
bRoyal Belfast Hospital for Sick Children, Belfast Health & Social Care Trust, Belfast, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurent Detalle
cAblynx nv, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ultan F. Power
aWellcome-Wolfson Institute for Experimental Medicine, Queens University Belfast, Belfast, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: u.power@qub.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

Abstract

Respiratory syncytial virus (RSV) causes severe lower respiratory tract infections in young infants. There are no RSV-specific treatments available. Ablynx has been developing an anti-RSV F-specific Nanobody®, ALX-0171. To characterise the therapeutic potential of ALX-0171 we exploited our well-differentiated primary pediatric bronchial epithelial cell (WD-PBEC)/RSV infection model, which replicates several hallmarks of RSV disease in vivo. Using 2 clinical isolates (BT2a; Memphis 37), we compared the therapeutic potential of ALX-0171 with palivizumab, which is currently prescribed for RSV prophylaxis in high-risk infants. ALX-0171 treatment (900 mM) at 24 h post-infection reduced apically released RSV titers to near or below the limit of detection within 24 h for both strains. Progressively lower doses resulted in concomitantly diminished RSV neutralisation. ALX-0171 was approximately 3 fold more potent in this therapeutic RSV/WD-PBEC model than palivizumab (mean IC50 = 346.9-363.6 nM and 1048-1090 nM for ALX-0171 and palivizumab, respectively), irrespective of the clinical isolate. When viral genomic copies (GC) were measured by RT-qPCR, the therapeutic effect was considerably less and GCs were only moderately reduced (0.62 – 1.28 Log10 copies/mL) by ALX-0171 treatment at 300 and 900 nM. Similar findings were evident for palivizumab. Therefore, ALX-0171 was very potent at neutralising RSV released from apical surfaces but only had a limited impact on virus replication. The data indicate a clear disparity between viable virus neutralisation and GC viral load, the latter of which does not discriminate between viable and neutralised RSV. This study validates the RSV/WD-PBEC model for the pre-clinical evaluation of RSV antivirals.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted October 10, 2019.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Comparative therapeutic potential of ALX-0171 and palivizumab against RSV clinical isolate infection of well-differentiated primary pediatric bronchial epithelial cell cultures
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Comparative therapeutic potential of ALX-0171 and palivizumab against RSV clinical isolate infection of well-differentiated primary pediatric bronchial epithelial cell cultures
Lindsay Broadbent, Hong Guo Parke, Lyndsey J. Ferguson, Andrena Miller, Michael D. Shields, Laurent Detalle, Ultan F. Power
bioRxiv 800326; doi: https://doi.org/10.1101/800326
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Comparative therapeutic potential of ALX-0171 and palivizumab against RSV clinical isolate infection of well-differentiated primary pediatric bronchial epithelial cell cultures
Lindsay Broadbent, Hong Guo Parke, Lyndsey J. Ferguson, Andrena Miller, Michael D. Shields, Laurent Detalle, Ultan F. Power
bioRxiv 800326; doi: https://doi.org/10.1101/800326

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Microbiology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4116)
  • Biochemistry (8819)
  • Bioengineering (6522)
  • Bioinformatics (23467)
  • Biophysics (11795)
  • Cancer Biology (9213)
  • Cell Biology (13327)
  • Clinical Trials (138)
  • Developmental Biology (7439)
  • Ecology (11416)
  • Epidemiology (2066)
  • Evolutionary Biology (15155)
  • Genetics (10439)
  • Genomics (14045)
  • Immunology (9174)
  • Microbiology (22163)
  • Molecular Biology (8814)
  • Neuroscience (47583)
  • Paleontology (350)
  • Pathology (1429)
  • Pharmacology and Toxicology (2492)
  • Physiology (3731)
  • Plant Biology (8082)
  • Scientific Communication and Education (1437)
  • Synthetic Biology (2221)
  • Systems Biology (6039)
  • Zoology (1253)